Purdue Pharma (Canada)
Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Real World Evidence of the Efficacy and Safety of FOQUEST
- Conditions
- Attention Deficit-Hyperactivity Disorder
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 257
- Registration Number
- NCT04152629
- Locations
- 🇨🇦
Matheson Centre for Mental Health Research & Education, University of Calgary, Calgary, Alberta, Canada
🇨🇦Adult ADHD Centeres at Pacific Coast Recovery Care, Burnaby, British Columbia, Canada
🇨🇦Medical Arts Health Research Group, Burnaby, British Columbia, Canada
PENTHROX™ in the Canadian Emergency Department (ED)
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 99
- Registration Number
- NCT03868436
- Locations
- 🇨🇦
Charles V Keating Emergency and Trauma Centre, QEII, Halifax, Nova Scotia, Canada
🇨🇦Royal Victoria Regional Health Centre, Barrie, Ontario, Canada
🇨🇦Markham Stouffville, Markham, Ontario, Canada
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 207
- Registration Number
- NCT03649230
- Locations
- 🇨🇦
Tom Baker Cancer Center, Calgary, Alberta, Canada
🇨🇦The Moncton Hospital, Moncton, New Brunswick, Canada
🇨🇦NSHA-QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- ADHD
- Interventions
- Drug: Placebo oral capsulesDrug: PRC-063 oral capsules
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 288
- Registration Number
- NCT03618030
- Locations
- 🇺🇸
Meridien Research Inc., Maitland, Florida, United States
🇺🇸Meridien Research, Lakeland, Florida, United States
🇺🇸South Shore Psychiatric Services, Hingham, Massachusetts, United States
PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
- Conditions
- ADHD
- Interventions
- Drug: Placebo oral capsulesDrug: PRC-063 oral capsules
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 156
- Registration Number
- NCT03172481
- Locations
- 🇺🇸
AVIDA Inc., Newport Beach, California, United States
🇺🇸Meridien Research Inc., Maitland, Florida, United States
🇺🇸Qps Mra Llc, Miami, Florida, United States